The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease.

ABSTRACT:

Background

There is limited evidence for the effectiveness of daclatasvir in patients whose hepatitis C threatens their life expectancy. The Named Patient Program in Europe included patients with advanced chronic hepatitis C, a life expectancy of less than 12 months and no other treatment options.

Methods

A retrospective multi-country cohort of patients with chronic hepatitis C who received daclatasvir as part of the Named Patient Program in Austria, Denmark, Spain, Sweden, Switzerland and the United Kingdom. Treatment response was defined as a sustained virologic response (unquantifiable hepatitis C RNA) at 12 weeks post treatment. We summarised the characteristics of the patients in this cohort and estimated the rate of sustained virologic response for patients receiving d

SUBMITTER: Young J 

PROVIDER: S-EPMC5219681 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature